Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Magnetically driven drug delivery systems improving targeted immunotherapy for colon-rectal cancer.

Grifantini R, Taranta M, Gherardini L, Naldi I, Parri M, Grandi A, Giannetti A, Tombelli S, Lucarini G, Ricotti L, Campagnoli S, De Camilli E, Pelosi G, Baldini F, Menciassi A, Viale G, Pileri P, Cinti C.

J Control Release. 2018 Jun 28;280:76-86. doi: 10.1016/j.jconrel.2018.04.052. Epub 2018 May 4.

PMID:
29733876
2.

TCTN2: a novel tumor marker with oncogenic properties.

Cano-Rodriguez D, Campagnoli S, Grandi A, Parri M, Camilli E, Song C, Jin B, Lacombe A, Pierleoni A, Bombaci M, Cordiglieri C, Ruiters MH, Viale G, Terracciano L, Sarmientos P, Abrignani S, Grandi G, Pileri P, Rots MG, Grifantini R.

Oncotarget. 2017 Aug 24;8(56):95256-95269. doi: 10.18632/oncotarget.20438. eCollection 2017 Nov 10.

3.

ERMP1, a novel potential oncogene involved in UPR and oxidative stress defense, is highly expressed in human cancer.

Grandi A, Santi A, Campagnoli S, Parri M, De Camilli E, Song C, Jin B, Lacombe A, Castori-Eppenberger S, Sarmientos P, Grandi G, Viale G, Terracciano L, Chiarugi P, Pileri P, Grifantini R.

Oncotarget. 2016 Sep 27;7(39):63596-63610. doi: 10.18632/oncotarget.11550.

4.

FAT1: a potential target for monoclonal antibody therapy in colon cancer.

Pileri P, Campagnoli S, Grandi A, Parri M, De Camilli E, Song C, Ganfini L, Lacombe A, Naldi I, Sarmientos P, Cinti C, Jin B, Grandi G, Viale G, Terracciano L, Grifantini R.

Br J Cancer. 2016 Jun 28;115(1):40-51. doi: 10.1038/bjc.2016.145. Epub 2016 Jun 21.

5.

Negatively charged AuNP modified with monoclonal antibody against novel tumor antigen FAT1 for tumor targeting.

Fan L, Campagnoli S, Wu H, Grandi A, Parri M, De Camilli E, Grandi G, Viale G, Pileri P, Grifantini R, Song C, Jin B.

J Exp Clin Cancer Res. 2015 Sep 15;34:103. doi: 10.1186/s13046-015-0214-x.

6.

Angiopoietin-like 7, a novel pro-angiogenetic factor over-expressed in cancer.

Parri M, Pietrovito L, Grandi A, Campagnoli S, De Camilli E, Bianchini F, MarchiĆ² S, Bussolino F, Jin B, Sarmientos P, Grandi G, Viale G, Pileri P, Chiarugi P, Grifantini R.

Angiogenesis. 2014 Oct;17(4):881-96. doi: 10.1007/s10456-014-9435-4. Epub 2014 Jun 6.

PMID:
24903490
7.

A novel polyclonal antibody library for expression profiling of poorly characterized, membrane and secreted human proteins.

Grifantini R, Pagani M, Pierleoni A, Grandi A, Parri M, Campagnoli S, Pileri P, Cattaneo D, Canidio E, Pontillo A, De Camilli E, Bresciani A, Marinoni F, Pedrazzoli E, Nogarotto R, Abrignani S, Viale G, Sarmientos P, Grandi G.

J Proteomics. 2011 Dec 21;75(2):532-47. doi: 10.1016/j.jprot.2011.08.018. Epub 2011 Sep 5.

PMID:
21920474
8.

Association of hepatitis C virus envelope proteins with exosomes.

Masciopinto F, Giovani C, Campagnoli S, Galli-Stampino L, Colombatto P, Brunetto M, Yen TS, Houghton M, Pileri P, Abrignani S.

Eur J Immunol. 2004 Oct;34(10):2834-42.

9.

The small extracellular loop of CD81 is necessary for optimal surface expression of the large loop, a putative HCV receptor.

Masciopinto F, Campagnoli S, Abrignani S, Uematsu Y, Pileri P.

Virus Res. 2001 Nov 28;80(1-2):1-10.

PMID:
11597743
10.

Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates.

Heile JM, Fong YL, Rosa D, Berger K, Saletti G, Campagnoli S, Bensi G, Capo S, Coates S, Crawford K, Dong C, Wininger M, Baker G, Cousens L, Chien D, Ng P, Archangel P, Grandi G, Houghton M, Abrignani S.

J Virol. 2000 Aug;74(15):6885-92.

11.

Structure-function analysis of hepatitis C virus envelope-CD81 binding.

Petracca R, Falugi F, Galli G, Norais N, Rosa D, Campagnoli S, Burgio V, Di Stasio E, Giardina B, Houghton M, Abrignani S, Grandi G.

J Virol. 2000 May;74(10):4824-30.

12.

Binding of hepatitis C virus to CD81.

Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, Weiner AJ, Houghton M, Rosa D, Grandi G, Abrignani S.

Science. 1998 Oct 30;282(5390):938-41.

13.

A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells.

Rosa D, Campagnoli S, Moretto C, Guenzi E, Cousens L, Chin M, Dong C, Weiner AJ, Lau JY, Choo QL, Chien D, Pileri P, Houghton M, Abrignani S.

Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):1759-63.

14.

Cumulative stabilizing effects of glycine to alanine substitutions in Bacillus subtilis neutral protease.

Margarit I, Campagnoli S, Frigerio F, Grandi G, De Filippis V, Fontana A.

Protein Eng. 1992 Sep;5(6):543-50.

PMID:
1438165
15.

Grafting of a calcium-binding loop of thermolysin to Bacillus subtilis neutral protease.

Toma S, Campagnoli S, Margarit I, Gianna R, Grandi G, Bolognesi M, De Filippis V, Fontana A.

Biochemistry. 1991 Jan 8;30(1):97-106.

PMID:
1899021
16.

Effect of Glu-143 and His-231 substitutions on the catalytic activity and secretion of Bacillus subtilis neutral protease.

Toma S, Campagnoli S, De Gregoriis E, Gianna R, Margarit I, Zamai M, Grandi G.

Protein Eng. 1989 Jan;2(5):359-64.

PMID:
2494652

Supplemental Content

Loading ...
Support Center